Should I buy or sell Genprex stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNPX shares. View GNPX analyst ratings or view top-rated stocks .

What is Genprex's stock price target for 2024?

1 brokerages have issued 12-month price targets for Genprex's stock. Their GNPX share price targets range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,198.7% from the stock's current price. View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts .

How have GNPX shares performed in 2023?

Genprex's stock was trading at $1.45 at the start of the year. Since then, GNPX stock has decreased by 84.1% and is now trading at $0.2310. View the best growth stocks for 2023 here .

Are investors shorting Genprex?

Genprex saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,340,000 shares, a drop of 18.3% from the October 31st total of 1,640,000 shares. Based on an average daily volume of 298,100 shares, the short-interest ratio is currently 4.5 days. View Genprex's Short Interest .

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our GNPX earnings forecast .

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Vaxart (VXRT) , Tonix Pharmaceuticals (TNXP) , Co-Diagnostics (CODX) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Advanced Micro Devices (AMD) .

Who are Genprex's major shareholders?

Genprex's stock is owned by a number of institutional and retail investors. Top institutional investors include AMH Equity Ltd (1.37%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine M Vaczy and John Rodney Varner. View institutional ownership trends .

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Genprex Stock Price, News & Analysis (NASDAQ:GNPX)

$0.23

0.00 (0.00%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.23
▼
$0.25
50-Day Range: $0.20
▼
$0.37
52-Week Range: $0.19
▼
$1.94

Volume: 309,720 shs
Average Volume: 181,848 shs
Market Capitalization: $13.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Genprex MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,198.7% Upside
$3.00 Price Target
Short Interest: Healthy
2.25% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.49) to ($0.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

226th out of 932 stocks

Pharmaceutical Preparations Industry

81st out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Genprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Genprex has a forecasted upside of 1,198.7% from its current price of $0.23.
Amount of Analyst Coverage
Genprex has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.25% of the outstanding shares of Genprex have been sold short.
Short Interest Ratio / Days to Cover
Genprex has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Genprex has recently decreased by 18.29%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Genprex does not currently pay a dividend.
Dividend Growth
Genprex does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Genprex has received a 75.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Genprex is -0.78.

0.6

News and Social Media Coverage

Search Interest
3 people have searched for GNPX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Genprex to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genprex insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.54% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.05% of the stock of Genprex is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Genprex are expected to grow in the coming year, from ($0.49) to ($0.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Genprex is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genprex is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Genprex has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Genprex Stock (NASDAQ:GNPX)

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GNPX Stock News Headlines

November 23, 2023 | finance.yahoo.com

Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer

November 16, 2023 | nz.finance.yahoo.com

Genprex, Inc. (GNPX) stock price, news, quote & history – Yahoo Finance

December 10, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 3, 2023 | finance.yahoo.com

Genprex to Present at BIO-Europe 2023

November 1, 2023 | finance.yahoo.com

Genprex to Present at BIO-Europe 2023 Conference

October 20, 2023 | finance.yahoo.com

Genprex Schedules, Hosts Virtual Key Opinion Leader Event

October 20, 2023 | finance.yahoo.com

Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"

October 6, 2023 | finance.yahoo.com

Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference

December 10, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 4, 2023 | finance.yahoo.com

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 21, 2023 | finance.yahoo.com

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

September 20, 2023 | finanznachrichten.de

NetworkNewsWire: Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

September 8, 2023 | finance.yahoo.com

Genprex to Present at Upcoming H.C. Wainwright Conference

September 4, 2023 | finance.yahoo.com

GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know

September 2, 2023 | finance.yahoo.com

Genprex Secures Patent Protection in 'Some of the Most Important Markets in the World'

August 24, 2023 | finance.yahoo.com

Genprex Appoints Regulatory Expert as It Drives Clinical Programs Forward

August 22, 2023 | finance.yahoo.com

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

August 13, 2023 | finance.yahoo.com

Genprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLC

August 5, 2023 | msn.com

Genprex (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination

August 5, 2023 | msn.com

Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering

August 5, 2023 | msn.com

Genprex (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh

July 28, 2023 | finance.yahoo.com

Genprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China

July 25, 2023 | finance.yahoo.com

Genprex Inc. Closes on $7.5M Registered Direct Offering

July 21, 2023 | finance.yahoo.com

Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

July 21, 2023 | finance.yahoo.com

Genprex Inc. Announces $7.5M Registered Direct Offering

July 20, 2023 | finance.yahoo.com

Genprex Enters Exclusive License Agreement with University of Pittsburgh

July 19, 2023 | msn.com

Genprex prices stock and warrants offering to raise $7.5M; shares fall

See More Headlines

Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/09/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/29/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GNPX
CUSIP: N/A
CIK: 1595248
Web: www.genprex.com
Phone: (877) 774-4679
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +1,198.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,740,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -194.71%
Return on Assets: -156.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.96
Quick Ratio: 2.96

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 59,440,000
Free Float: 52,576,000
Market Cap: $13.73 million
Optionable: Not Optionable
Beta: -0.10

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. John Rodney Varner (Age 66)
Co-Founder, Chairman, President & CEO
Comp: $886.97k
Mr. Ryan M. Confer M.S. (Age 41)
Chief Financial Officer
Comp: $606.57k
Ms. Catherine M. Vaczy Esq. (Age 62)
Executive VP, General Counsel, Corporate Secretary & Chief Strategy Officer
Comp: $704.93k
Mr. David M. Schloss
Senior Vice President of Human Resources
Mr. Thomas C. Gallagher Esq.
Senior Vice President of Intellectual Property & Licensing
Dr. Mark S. Berger M.D. (Age 68)
Chief Medical Officer
Dr. Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality
Dr. Jack A. Roth F.A.C.S.
M.D., Chairman of Scientific & Medical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GNPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genprex stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNPX shares.
View GNPX analyst ratings or view top-rated stocks.
What is Genprex's stock price target for 2024?: 1 brokerages have issued 12-month price targets for Genprex's stock. Their GNPX share price targets range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,198.7% from the stock's current price.
View analysts price targets for GNPX or view top-rated stocks among Wall Street analysts.
How have GNPX shares performed in 2023?: Genprex's stock was trading at $1.45 at the start of the year. Since then, GNPX stock has decreased by 84.1% and is now trading at $0.2310.
View the best growth stocks for 2023 here.
Are investors shorting Genprex?: Genprex saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,340,000 shares, a drop of 18.3% from the October 31st total of 1,640,000 shares. Based on an average daily volume of 298,100 shares, the short-interest ratio is currently 4.5 days.
View Genprex's Short Interest.
When is Genprex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our GNPX earnings forecast.

How were Genprex's earnings last quarter?: Genprex, Inc. (NASDAQ:GNPX) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02.
What other stocks do shareholders of Genprex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), Advanced Micro Devices (AMD).
Who are Genprex's major shareholders?: Genprex's stock is owned by a number of institutional and retail investors. Top institutional investors include AMH Equity Ltd (1.37%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Catherine M Vaczy and John Rodney Varner.
View institutional ownership trends.
How do I buy shares of Genprex?: Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GNPX) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Genprex Stock Price, News & Analysis (NASDAQ:GNPX)

Genprex MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Genprex Stock (NASDAQ:GNPX)

GNPX Stock Price History

GNPX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GNPX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™